2025-08-13T12:53:44+00:00 2024-09-30 346565596 ERNST & YOUNG US LLP 18101 VON KARMAN AVENUE IRVINE CA 92612 990 2023-10-01 331092191 THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION TRAN 6023438411 445 N 5TH STREET 120 PHOENIX AZ 85004 ERIN MASSEY CHIEF DEVELOPMENT OFFICER 2025-08-13 true Kara Adams P00023315 9497942300 2025-08-01 2023 2025-03-06 01:10:19Z ERIN MASSEY 445 N 5TH STREET 120 PHOENIX AZ 85004 11106714 false X WWW.TGEN.ORG/GIVING/TGEN-FOUNDATION/ X 2004 AZ Fundraising and development functions for The Translational Genomics Research Institute ("TGen"), Western Regional Medical Center, Inc. ("COH Phoenix") and their respective affiliates, which are 501(c)(3) tax-exempt organizations. 23 19 0 100 0 0 14552517 10455284 0 0 848247 591893 0 0 15400764 11047177 14873631 9708783 0 0 1556222 1451807 0 1717612 557424 458622 16987277 11619212 -1586513 -572035 22611724 22786653 9981778 10706428 12629946 12080225 Fundraising and development functions for The Translational Genomics Research Institute ("TGen"), Western Regional Medical Center, Inc. ("COH Phoenix") and their respective affiliates, which are 501(c)(3) tax-exempt organizations. false false 9708783 9708783 0 PLEASE SEE SCHEDULE O 9708783 true true false false false false false false true false false false false false true false true false false false false false false false false false true false true false false false false false false false false true false false false false true true true false false true X 4 0 true 0 false false false false false true true false false false false false false X 23 19 true false true false true true true true false false false true true true true true true true true false X TRACY KARNS 6023438415 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 BENNETT DORRANCE BOARD MEMBER/CHAIRMAN 1.0 1.0 X X 0 0 0 ERIN MASSEY CHIEF DEVELOPMENT OFFICER 40.0 0.0 X X 0 360363 25660 KEN KENDRICK BOARD MEMBER/SECRETARY 1.0 0.0 X X 0 0 0 RICHARD J LEHMANN BOARD MEMBER/TREASURER 1.0 0.0 X X 0 0 0 ALAN POWELL BOARD MEMBER 1.0 0.0 X 0 0 0 BILL POPE BOARD MEMBER 1.0 0.0 X 0 0 0 CATHERINE IVY BOARD MEMBER 1.0 0.0 X 0 0 0 DAVID LANE BOARD MEMBER 1.0 0.0 X 0 0 0 FRED SHAULIS BOARD MEMBER 1.0 0.0 X 0 0 0 GLENN D STEELE MD PHD BOARD MEMBER 1.0 8.0 X 0 0 0 HOWARD YOUNG BOARD MEMBER 1.0 0.0 X 0 0 0 J DANFORTH QUAYLE BOARD MEMBER 1.0 0.0 X 0 0 0 JEFFREY M TRENT PHD BOARD MEMBER 1.0 39.0 X 0 1532966 343288 KEVIN TULIPANA DO MS BOARD MEMBER 1.0 60.0 X 0 566130 39884 LYNDA CARTER ALTMAN BOARD MEMBER 1.0 0.0 X 0 0 0 MICHEAL KAPLAN BOARD MEMBER 1.0 0.0 X 0 0 0 MIKE INGRAM BOARD MEMBER 1.0 0.0 X 0 0 0 PHIL FRANCIS BOARD MEMBER 1.0 0.0 X 0 0 0 STEVE HILTON BOARD MEMBER 1.0 0.0 X 0 0 0 STEVE STAGNER BOARD MEMBER 1.0 0.0 X 0 0 0 TERESA BURLESON BOARD MEMBER/TGEN COO 1.0 39.0 X 0 718000 31378 TROY RICHARDS BOARD MEMBER 1.0 0.0 X 0 0 0 WILLIAM J POST BOARD MEMBER 1.0 9.0 X 0 0 0 MANUEL ESTRADA CFO/ASSISTANT TREASURER 0.0 39.0 X 0 439142 36511 0 3616601 476721 0 false true false 0 10455284 59537 10455284 0 0 0 0 0 593050 593050 0 0 58380 59537 -1157 0 -1157 -1157 0 0 0 0 0 11047177 0 0 591893 9708783 9708783 0 0 0 0 0 0 346845 0 43895 302950 0 0 0 0 837158 0 74505 762653 0 0 0 0 267804 0 26780 241024 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4750 0 0 4750 27146 0 2715 24431 155510 0 15551 139959 8924 0 892 8032 0 0 0 0 101076 0 10108 90968 8672 0 867 7805 0 0 0 0 150044 0 15004 135040 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 DUES & SUBSCRIPTIONS 2500 0 2500 0 0 0 0 0 11619212 9708783 192817 1717612 0 0 0 0 0 0 19791463 14205223 2514609 8402838 303095 147664 0 0 0 0 0 0 0 0 2557 30928 0 0 0 0 0 0 0 0 0 0 0 0 22611724 22786653 9912232 10636882 0 0 69546 69546 0 0 0 0 0 0 0 0 0 0 0 0 9981778 10706428 X -10015042 -10528165 22644988 22608390 0 0 0 0 0 0 12629946 12080225 22611724 22786653 -572035 22314 0 0 0 0 X false true X true false X 22935783 3753754 11410329 14552517 10455284 63107667 0 0 22935783 3753754 11410329 14552517 10455284 63107667 32004997 31102670 127078 18699 161258 848247 593050 1748332 0 0 0 0 0 0 0 64855999 0 0.4796 0.5297 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 2587562 5172425 119773 7353 7872407 2313650 172948 114257 13293 2587562 2143985 171950 5068 7353 2313650 1962082 173542 14478 6117 2143985 1562158 378481 28796 7353 1962082 0.0 0.01 0.99 false false 0 X Schedule D, Part V, Line 4 Intended uses of endowment funds TGEN FOUNDATION CLASSIFIES AS PERMANENTLY RESTRICTED NET ASSETS (1) THE ORIGINAL VALUE OF THE GIFT DONATED TO THE PERMANENT ENDOWMENT, (2) THE ORIGINAL VALUE OF SUBSEQUENT GIFTS DONATED TO THE PERMANENT ENDOWMENT, AND (3) ACCUMULATIONS TO THE PERMANENT ENDOWMENT MADE IN ACCORDANCE WITH THE DIRECTION OF THE APPLICABLE DONOR GIFT INSTRUMENT. TGEN FOUNDATION HAS A TEMPORARILY RESTRICTED ASSET WHICH HAS BEEN DESIGNATED TO SUPPORT SUMMER INTERNS EACH YEAR AT TGEN. TGEN FOUNDATION'S POLICY FOR APPROPRIATING THE DISTRIBUTION OF ITS SUMMER INTERNSHIP PROGRAM ENDOWMENT HAS BEEN DESIGNED TO SUPPORT A GRANT TO TGEN FOR AN INTERN EACH YEAR FOR 25 YEARS. THE FOUNDATION CONSIDERED THE LONG-TERM EXPECTED RETURN ON ITS ENDOWMENT. TGEN FOUNDATION HAS RESTRICTED ASSETS FOR THE ESTABLISHMENT OF AN ENDOWED CHAIR IN BRAIN CANCER RESEARCH AND AN ENDOWED CHAIR IN PANCREATIC CANCER RESEARCH. TGEN FOUNDATION ALSO HAS RESTRICTED ASSETS WHICH ALLOW USE OF ANY INVESTMENT INCOME FOR OPERATING EXPENSES. Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote THE FOLLOWING PARAGRAPH IS FROM THE CITY OF HOPE CONSOLIDATED AUDITED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2024 (WHICH INCLUDES CITY OF HOPE, CITY OF HOPE NATIONAL MEDICAL CENTER (THE "CENTER"), CITY OF HOPE MEDICAL FOUNDATION (THE "FOUNDATION"), AND BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE (THE "INSTITUTE") (COLLECTIVELY, THE "OBLIGATED GROUP"); THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE AND ITS AFFILIATES ("TGEN"); SOUTHERN CALIFORNIA RADIATION ONCOLOGY, LLC ("SCRO"); ACCESSHOPE, LLC ("AH"); STEPHENSON PANCREATIC CANCER RESEARCH, LLC (SPCR); AND COH HOLDCO INC. ("HOLDCO"), THE PARENT OF CANCER TREATMENT CENTERS OF AMERICA ENTITIES ("CTCA ENTITIES") (COLLECTIVELY, THE "AFFILIATED GROUP"). THESE ENTITIES REPRESENT THE CONSOLIDATED CITY OF HOPE ORGANIZATION (COLLECTIVELY REFERRED TO AS "CITY OF HOPE")). CITY OF HOPE IS EXEMPT FROM FEDERAL INCOME TAX UNDER SECTION 501(A) AS DESCRIBED IN SECTION 501(C)(3) OF THE U.S. INTERNAL REVENUE CODE. CITY OF HOPE, THE CENTER, THE FOUNDATION, AND THE INSTITUTE ARE EXEMPT FROM CALIFORNIA STATE FRANCHISE AND INCOME TAX UNDER SECTION 23701(D) OF THE CALIFORNIA REVENUE AND TAXATION CODE. ASC 740, INCOME TAXES, CLARIFIES THE ACCOUNTING FOR INCOME TAXES BY PRESCRIBING A MINIMUM RECOGNITION THRESHOLD THAT A TAX POSITION IS REQUIRED TO MEET BEFORE BEING RECOGNIZED IN THE CONSOLIDATED FINANCIAL STATEMENTS. ASC 740 ALSO PROVIDES GUIDANCE ON DE-RECOGNITION, MEASUREMENT, CLASSIFICATION, INTEREST AND PENALTIES, DISCLOSURE, AND TRANSITION. THE GUIDANCE CONTAINED IN ASC 740 IS APPLICABLE TO PASS-THROUGH ENTITIES AND TAX-EXEMPT ORGANIZATIONS. CITY OF HOPE HAS NO SIGNIFICANT UNCERTAIN TAX POSITIONS OR TAX LIABILITY FOR TAX BENEFITS, INTEREST, OR PENALTIES ACCRUED AS OF SEPTEMBER 30, 2024 OR 2023. true THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE 445 N 5TH ST STE 600 PHOENIX AZ 85004 753065445 501(C)(3) 9708783 0 FUNDRAISING FOR TGEN AND COH PHX 1 0 Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds TGEN Foundation monitors its grants to ensure such grants are used for proper purposes via regular financial reviews. false true false false false false false true false ERIN MASSEY CHIEF DEVELOPMENT OFFICER 0 319615 0 40000 0 748 0 19385 0 6275 0 386023 0 0 JEFFREY M TRENT PHD BOARD MEMBER 0 878368 0 542543 0 112055 0 312181 0 31107 0 1876254 0 198163 TERESA BURLESON BOARD MEMBER/TGEN COO 0 577628 0 138299 0 2073 0 19740 0 11638 0 749378 0 0 KEVIN TULIPANA DO MS BOARD MEMBER 0 396269 0 169861 0 0 0 13200 0 26684 0 606014 0 0 MANUEL ESTRADA CFO/ASSISTANT TREASURER 0 376611 0 61289 0 1242 0 19740 0 16771 0 475653 0 0 Schedule J, Part I, Line 3 Arrangement used to establish the top management official's compensation TGEN FOUNDATION DOES NOT DETERMINE OR PAY ANY COMPENSATION OR BENEFITS. ALL COMPENSATION AND BENEFITS ARE DETERMINED AND PAID BY TGEN, A RELATED TAX-EXEMPT ORGANIZATION. Schedule J, Part I, Line 4b Supplemental nonqualified retirement plan CITY OF HOPE HAS A NON-QUALIFIED SECTION 457(F) EXECUTIVE SUPPLEMENTAL ACCUMULATION PLAN THAT IS DESIGNED AND MAINTAINED TO PROVIDE A SELECT GROUP OF MANAGEMENT OR HIGHLY COMPENSATED EMPLOYEES WITH DEFERRED COMPENSATION. THE PLAN VESTS AFTER THREE (3) FISCAL YEARS OF SERVICE AND THE VESTED TOTALS ARE INCLUDED IN SCHEDULE J, PART II, COLUMN B (III). PRIOR TO VESTING, THE ANNUAL AMOUNTS ARE INCLUDED IN SCHEDULE J, PART II, COLUMN C. PURSUANT TO THE PLAN DOCUMENT, VESTED PARTICIPANTS ARE ENTITLED TO WITHDRAW FROM THEIR VESTED ACCOUNT AN AMOUNT EQUAL TO THE FEDERAL, STATE, LOCAL AND FICA TAXES THEY OWE. THESE AMOUNTS ARE REMITTED TO THE APPROPRIATE TAXING AUTHORITIES ON BEHALF OF THE PARTICIPANTS. None of the individuals reported on Schedule J, Part II received a distribution from the plan this year. Schedule J, Part I, Line 7 Non-fixed payments THE TRANSLATIONAL GENOMICS RESEARCH INSTITUE FOUNDATION'S EXECUTIVES AND CERTAIN KEY EMPLOYEES ARE ELIGIBLE TO RECEIVE INCENTIVE COMPENSATION UNDER AN ANNUAL INCENTIVE PLAN (AIP) TIED TO ORGANIZATIONAL KEY PERFORMANCE INDICATORS AND INDIVIDUAL OBJECTIVES. THE KEY PERFORMANCE INDICATORS REFLECT KEY AREAS OF STRATEGIC FOCUS AND THE EXEMPT HEALTHCARE MISSION OF CITY OF HOPE AND AFFILIATES AND ARE BOTH FINANCIAL AND NON-FINANCIAL. THE POTENTIAL INCENTIVE COMPENSATION IS BASED ON A WEIGHTED AVERAGE AMONG ALL INDICATORS AND IS PAID AS A PERCENTAGE OF EACH INDIVIDUAL PARTICIPANT'S BASE COMPENSATION. THE KEY PERFORMANCE INDICATORS ARE WEIGHTED BASED ON THE PARTICIPANT'S PRIMARY AREA(S) OF RESPONSIBILITY, WITH ORGANIZATIONAL KEY PERFORMANCE INDICATORS WEIGHTED FROM 70 PERCENT TO 90 PERCENT, AND AND THE INDIVIDUAL OBJECTIVES WEIGHTED FROM 10 PERCENT TO 30 PERCENT. THE AIP IS UNDER THE CONTROL OF, AND ADMINISTERED BY, THE INDEPENDENT DIRECTORS SERVING ON THE EXECUTIVE COMPENSATION AND GOVERNANCE COMMITTEE. TO BE ELIGIBLE, THE PARTICIPANTS IN THE AIP MUST BE EMPLOYED BY CITY OF HOPE AT THE TIME OF THE INCENTIVE PLAN PAYMENT, AND BE MEETING OR EXCEEDING PERFORMANCE EXPECTATIONS. CITY OF HOPE MAY, IN ITS DISCRETION, CANCEL ALL OR A PORTION OF ANY INCENTIVE PLAN PAYMENT OR AWARD TO ANY PARTICIPANT, WHETHER BEFORE OR FOLLOWING PAYMENT OF SUCH AWARD, SUBJECT TO COMPLIANCE WITH APPLICABLE LAW, UNDER THE FOLLOWING CIRCUMSTANCES (CANCELLATION POLICY): A) AN INCENTIVE PLAN PAYMENT OR AWARD IS MADE FOR A FISCAL PERIOD AND CITY OF HOPE SUBSEQUENTLY RESTATES OR OTHERWISE ADJUSTS THE ANNUAL PERFORMANCE MEASUREMENT CALCULATION IN A MANNER THAT WOULD REDUCE THE SIZE OF THE AWARD OR PAYMENT, OR; B) AN INCENTIVE PLAN PAYMENT OR AWARD IS MADE FOR A FISCAL PERIOD AND CITY OF HOPE SUBSEQUENTLY DETERMINES THAT ONE OF MORE OF THE ANNUAL PERFORMANCE MEASUREMENT CALCULATIONS ON WHICH THE AWARD IS BASED OR IS PAID ARE MATERIALLY INACCURATE. THE AIP INCENTIVE COMPENSATION EARNED FOR FISCAL YEAR 2023 WAS PAID IN CALENDAR YEAR 2023 AND THESE AMOUNTS HAVE BEEN REPORTED IN SCHEDULE J, PART II, COLUMN (B)(II). ADDITIONALLY, CITY OF HOPE HAS AN EXECUTIVE LONG-TERM INCENTIVE (LTI) PLAN FOR CERTAIN EXECUTIVES WHICH IS DESIGNED TO DRIVE LONG-TERM ORGANIZATIONAL PERFORMANCE AND TRANSFORMATION BY ALIGNING EXECUTIVES WITH THE MULTI-YEAR STRATEGIC PLAN AND INCENTIVIZING THEM FOR ACHIEVING KEY ORGANIZATIONAL AND STRATEGIC OBJECTIVES AND GOALS. WITH THREE-YEAR VESTING PERIODS, THE PLAN ALSO PROVIDES A MEANS FOR RETAINING KEY EXECUTIVE TALENT. THE PERFORMANCE PERIOD OF THE PLAN (CYCLE 9) RAN FROM OCTOBER 1, 2020 THROUGH SEPTEMBER 30, 2023 WITH A NEW THREE-YEAR PERFORMANCE PERIOD BEGINNING EACH OCTOBER 1ST THEREAFTER (E.G., CYCLE 10 RUNS FROM OCTOBER 1, 2021 THROUGH SEPTEMBER 30, 2024). TO BE ELIGIBLE TO PARTICIPATE IN ANY PAYOUT UNDER THE PLAN, PARTICIPANTS MUST BE ACTIVELY EMPLOYED BY CITY OF HOPE AT THE TIME OF THE INCENTIVE PLAN PAYMENT, AND BE MEETING OR EXCEEDING PERFORMANCE EXPECTATIONS. WHILE THE PLAN DOES MEET THE REQUIREMENTS FOR A SUBSTANTIAL RISK OF FORFEITURE, AS OF THE CALENDAR YEAR ENDING DECEMBER 31, 2023, THE POTENTIAL LTI AMOUNTS HAVE BEEN ESTIMATED AND ACCRUED DURING THE CURRENT TAX YEAR AND ARE REPORTED AS DEFERRED COMPENSATION TO THE PLAN PARTICIPANTS IN SCHEDULE J, PART II, COLUMN (C). THE LTI PLAN IS SUBJECT TO THE SAME CANCELLATION POLICY AS THE AIP DESCRIBED PREVIOUSLY. PARTICIPANTS WHO MET THE ELIGIBILITY CRITERIA RECEIVED A PAYOUT OF PLAN CYCLE 9 LTI INCENTIVES (OCTOBER 1, 2020 THROUGH SEPTEMBER 30, 2023) IN DECEMBER 2023. THESE AMOUNTS HAVE BEEN REFLECTED IN SCHEDULE J, PART II, COLUMN (B)(II). X 5 59537 Market value 0 false true false Form 990, Part V, Line 2a FORM 990, PART V, LINE 2A; PART VII, SECTION A; AND PART IX TGEN FOUNDATION DOES NOT HAVE EMPLOYEES, BUT SHARES THE COST OF PERSONNEL, SERVICES, FACILITIES AND EXPENSES WITH TGEN, A RELATED TAX-EXEMPT ORGANIZATION. Form 990, Part VI, Line 2 Family/business relationships amongst interested persons MICHEAL KAPLAN AND BENNETT DORRANCE - Family relationship Form 990, Part VI, Line 4 Significant changes to organizational documents THE TGEN FOUNDATION ARTICLES OF INCORPORATION WERE AMENDED TO ADD A SUPPORTED ORGANIZATION AS FOLLOWS: The corporation is organized exclusively to benefit The Translational Genomics Research Institute, an Arizona nonprofit corporation ("TGen"), Western Regional Medical Center, Inc., an Arizona nonprofit corporation ("COH Phoenix") and their respective Affiliates, by supporting TGen's, COH Phoenix's and their respective Affiliates' fundraising and development functions consistent with TGen' s, COH Phoenix's and their respective Affiliates' respective purposes, including indirectly through the support of or cooperation with organizations affiliated with TGen, COH Phoenix and their respective Affiliates that are exempt from tax under Section 501(c)(3) of the Internal Revenue Code of 1986, as amended (the "Code"), and contributions to which are deductible under Section 170(c)(2) of the Code. Form 990, Part VI, Line 6 Classes of members or stockholders THE SOLE CORPORATE MEMBER OF TGEN FOUNDATION IS THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN). Form 990, Part VI, Line 7a Members or stockholders electing members of governing body TGEN, AS THE SOLE CORPORATE MEMBER OF TGEN FOUNDATION, HAS THE RIGHT TO ELECT THE BOARD OF DIRECTORS OF TGEN FOUNDATION. Form 990, Part VI, Line 7b Decisions requiring approval by members or stockholders THE SOLE CORPORATE MEMBER'S APPROVAL SHALL BE REQUIRED ON: (A) THE ELECTION AND REMOVAL OF ELECTED DIRECTORS AS SET FORTH IN THE BYLAWS; (B) THE ADOPTION OF ANY PLAN OF MERGER OR CONSOLIDATION; (C) THE SALE OF ALL OR SUBSTANTIALLY ALL THE FOUNDATION'S ASSETS IN A SINGLE TRANSACTION OR SERIES OF RELATED TRANSACTIONS; (D) THE AMENDMENT OF THE FOUNDATION'S ARTICLES OF INCORPORATION OR BYLAWS; (E) THE INSTITUTION, OR CONSENT TO INSTITUTION, OF PROCEEDINGS TO ADJUDICATE THE FOUNDATION BANKRUPT OR INSOLVENT, OR THE FILING OF A PETITION SEEKING OR CONSENTING TO REORGANIZATION OR RELIEF UNDER ANY LAW RELATING TO BANKRUPTCY, INSOLVENCY, OR OTHER RELIEF FOR DEBTORS, OR THE CONSENT TO THE APPOINTMENT OF A RECEIVER, LIQUIDATOR, ASSIGNEE, TRUSTEE, SEQUESTRATOR (OR SIMILAR OFFICIAL) OF THE FOUNDATION OR OF ALL OR ANY SUBSTANTIAL PART OF ITS PROPERTY, OR THE MAKING OF ANY ASSIGNMENT FOR THE BENEFIT OF CREDITORS, OR THE ADMISSION IN WRITING OF THE FOUNDATION'S INABILITY TO PAY ITS DEBTS GENERALLY AS THEY BECOME DUE, OR ANY STEPS IN FURTHERANCE OF SUCH ACTIONS; AND (F) THOSE MATTERS UPON WHICH THE MEMBER IS GRANTED APPROVAL RIGHTS IN THE ARTICLES OF INCORPORATION, BYLAWS, OR THE ARIZONA NONPROFIT CORPORATION ACT. THE SOLE CORPORATE MEMBER HAS THE FOLLOWING RESERVE POWERS: (A) APPOINT AND REMOVE THE PRESIDENT; (B) APPROVE THE ESTABLISHMENT OF NEW CORPORATE PARTNERSHIP ENTITIES CREATED OR JOINED BY THE FOUNDATION; (C) APPROVE THE FOUNDATION'S EXECUTION OF MATERIAL CONTRACTS; AND (D) APPROVE THE FOUNDATION'S INCURRENCE OF MATERIAL DEBTS. Form 990, Part VI, Line 8b Documentation of meetings held by committees of governing body There are no committees with the authority to act on behalf of the governing body. Form 990, Part VI, Line 11b Review of form 990 by governing body THE FORM 990 IS PREPARED BY AN OUTSIDE ACCOUNTING FIRM BASED ON INFORMATION PROVIDED BY THE TGEN FINANCE DEPARTMENT. THE FORM 990 IS THEN REVIEWED BY THE FINANCE DEPARTMENT, OTHER MEMBERS OF MANAGEMENT AND THE AUDIT AND COMPLIANCE COMMITTEE OF THE CITY OF HOPE. THE FORM 990 IS POSTED ON THE BOARD WEBSITE FOR BOARD REVIEW PRIOR TO FILING WITH THE IRS. Form 990, Part VI, Line 12c Conflict of interest policy TGEN DISTRIBUTES A CONFLICT OF INTEREST QUESTIONNAIRE ANNUALLY TO ALL DIRECTOR LEVEL POSITIONS AND ABOVE, IN ADDITION TO ANY OFFICERS AND KEY EMPLOYEES DESIGNATED BY THE CONFLICT OF INTEREST COMMITTEE. THE QUESTIONNAIRES ARE REVIEWED BY TGEN'S FINANCE DEPARTMENT AND THE OFFICE OF RESEARCH COMPLIANCE. THOSE EMPLOYEES WITH CONFLICTS ARE FURTHER REVIEWED BY THE CONFLICT OF INTEREST COMMITTEE TO ENSURE AN APPROPRIATE PLAN IS SET FORTH. UPDATES TO THE LIST ARE HANDLED ON AN AS-NEEDED BASIS, BASED ON CONTRACT REVIEWS AND EMPLOYEE INFORMATION. Form 990, Part VI, Line 15a Process to establish compensation of top management official THE EXECUTIVE COMPENSATION AND GOVERNANCE COMMITTEE OF THE CITY OF HOPE BOARD OF DIRECTORS ("COMMITTEE"), PURSUANT TO A DELEGATION OF AUTHORITY FROM THE CITY OF HOPE BOARD OF DIRECTORS AND THE TGEN BOARD OF DIRECTORS, IS RESPONSIBLE FOR SETTING THE COMPENSATION OF THE TOP MANAGEMENT OFFICIAL. THE DIRECTORS ON THIS COMMITTEE ARE INDEPENDENT AND ADHERE TO A STRICT CONFLICT OF INTEREST POLICY. DELIBERATION AND DECISION MAKING ARE SUBSTANTIATED IN THE MINUTES OF THE COMMITTEE'S MEETINGS. THE MINUTES ARE REVIEWED AND APPROVED AT THE NEXT MEETING OF THE COMMITTEE. AS PART OF THE DELIBERATION PROCESS, THE COMMITTEE RECEIVES ADVICE FROM AN INDEPENDENT, THIRD-PARTY COMPENSATION CONSULTANT WITH RESPECT TO EXECUTIVE COMPENSATION, INCLUDING REVIEW OF COMPARABLE AND BENCHMARK DATA, CURRENT COMPENSATION PHILOSOPHY, STRUCTURE, AND ADMINISTRATION OF THE EXECUTIVE COMPENSATION PROGRAMS AT CITY OF HOPE AND AFFILIATES. THE COMMITTEE CARRIES OUT THE BOARD OF DIRECTORS' OVERALL RESPONSIBILITIES RELATING TO EXECUTIVE COMPENSATION. THE EXECUTIVE COMPENSATION PHILOSOPHY IS DESIGNED TO ASSIST IN ATTRACTING AND RETAINING THE CALIBER OF EXECUTIVE LEADERSHIP REQUIRED TO ENABLE CITY OF HOPE TO ACHIEVE THE HIGHEST LEVELS OF COMMUNITY BENEFIT, IMPACT TO CLINICAL CARE, QUALITY RESEARCH AND EFFICIENT PHILANTHROPIC DEVELOPMENT. UNDER THE AIP AND LTI DESCRIBED IN SCHEDULE J, A SUBSTANTIAL PORTION OF EXECUTIVE COMPENSATION IS LINKED DIRECTLY TO PERFORMANCE GOALS APPROVED IN ADVANCE. AS A RESULT, PERFORMANCE COMPENSATION MAY VARY FROM YEAR TO YEAR. GOAL SETTING UNDER THE AIP IS TIED TO ANNUAL PERFORMANCE, INCLUDING THE ATTAINMENT OF SPECIFIC BUSINESS OBJECTIVES FOR STRATEGIC AND FINANCIAL PERFORMANCE AS WELL AS NON-FINANCIAL MEASURES SUCH AS PATIENT SATISFACTION AND QUALITY OF PATIENT CARE. THE LTI IS DESIGNED TO DRIVE LONG-TERM ORGANIZATIONAL PERFORMANCE AND TRANSFORMATION BY ALIGNING EXECUTIVES WITH THE MULTI YEAR STRATEGIC PLAN AND INCENTIVIZING THEM TO ACHIEVE KEY ORGANIZATIONAL AND STRATEGIC OBJECTIVES AND GOALS. WITH THREE-YEAR VESTING PERIODS, THE LTI ALSO PROVIDES A MEANS FOR RETAINING KEY EXECUTIVE TALENT. THE COMMITTEE CONDUCTS ANNUAL COMPENSATION REVIEWS FOR THE TOP MANAGEMENT OFFICIAL IN DECEMBER. Form 990, Part VI, Line 15b Process to establish compensation of other employees THE EXECUTIVE COMPENSATION AND GOVERNANCE COMMITTEE OF THE CITY OF HOPE BOARD OF DIRECTORS ("COMMITTEE") PURSUANT TO A DELEGATION OF AUTHORITY FROM THE CITY OF HOPE BOARD OF DIRECTORS AND THE TGEN BOARD OF DIRECTORS, IS RESPONSIBLE FOR SETTING THE COMPENSATION OF, OR ESTABLISHING COMPENSATION LEVELS FOR TOTAL COMPENSATION CONSISTENT WITH CITY OF HOPE'S COMPENSATION PHILOSOPHY, FOR SENIOR LEADERS AT THE SENIOR VICE PRESIDENT OR EQUIVALENT LEVEL. THE DIRECTORS ON THIS COMMITTEE ARE INDEPENDENT AND ADHERE TO A STRICT CONFLICT OF INTEREST POLICY. DELIBERATION AND DECISION MAKING ARE SUBSTANTIATED IN THE MINUTES OF THE COMMITTEE'S MEETINGS. THE MINUTES ARE REVIEWED AND APPROVED AT THE NEXT MEETING OF THE COMMITTEE. AS PART OF THE DELIBERATION PROCESS, THE COMMITTEE RECEIVES ADVICE FROM AN INDEPENDENT, THIRD-PARTY COMPENSATION CONSULTANT WITH RESPECT TO EXECUTIVE COMPENSATION, INCLUDING REVIEW OF COMPARABLE AND BENCHMARK DATA, CURRENT COMPENSATION PHILOSOPHY, STRUCTURE, AND ADMINISTRATION OF THE EXECUTIVE COMPENSATION PROGRAMS AT CITY OF HOPE AND AFFILIATES. THE COMMITTEE CARRIES OUT THE BOARD OF DIRECTORS' OVERALL RESPONSIBILITIES RELATING TO EXECUTIVE COMPENSATION. THE EXECUTIVE COMPENSATION PHILOSOPHY IS DESIGNED TO ASSIST IN ATTRACTING AND RETAINING THE CALIBER OF EXECUTIVE LEADERSHIP REQUIRED TO ENABLE CITY OF HOPE TO ACHIEVE THE HIGHEST LEVELS OF COMMUNITY BENEFIT, IMPACT TO CLINICAL CARE, QUALITY RESEARCH AND EFFICIENT PHILANTHROPIC DEVELOPMENT. UNDER THE AIP AND LTI DESCRIBED IN SCHEDULE J, A SUBSTANTIAL PORTION OF EXECUTIVE COMPENSATION IS LINKED DIRECTLY TO PERFORMANCE GOALS APPROVED IN ADVANCE. AS A RESULT, PERFORMANCE COMPENSATION MAY VARY FROM YEAR TO YEAR. GOAL SETTING UNDER THE AIP IS TIED TO ANNUAL PERFORMANCE, INCLUDING THE ATTAINMENT OF SPECIFIC BUSINESS OBJECTIVES FOR STRATEGIC AND FINANCIAL PERFORMANCE AS WELL AS NON-FINANCIAL MEASURES SUCH AS PATIENT SATISFACTION AND QUALITY OF PATIENT CARE. THE LTI IS DESIGNED TO DRIVE LONG-TERM ORGANIZATIONAL PERFORMANCE AND TRANSFORMATION BY ALIGNING EXECUTIVES WITH THE MULTI YEAR STRATEGIC PLAN AND INCENTIVIZING THEM TO ACHIEVE KEY ORGANIZATIONAL AND STRATEGIC OBJECTIVES AND GOALS. WITH THREE-YEAR VESTING PERIODS, THE LTI ALSO PROVIDES A MEANS FOR RETAINING KEY EXECUTIVE TALENT. THE COMMITTEE CONDUCTS ANNUAL COMPENSATION REVIEWS IN DECEMBER TO SET COMPENSATION LEVELS, OR WHERE THE PROPOSED COMPENSATION EXCEEDS COMPENSATION LEVELS ESTABLISHED BY THE COMMITTEE, COMPENSATION FOR SENIOR LEADERS AT THE SENIOR VICE PRESIDENT OR EQUIVALENT LEVEL. Form 990, Part VI, Line 19 Required documents available to the public TGEN FOUNDATION PROVIDES ITS GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY TO THE GENERAL PUBLIC UPON REQUEST. FORM 990, PART III, LINE 4A SCIENCE, BY NATURE, IS AN ITERATIVE PROCESS: A QUESTION AND ANSWER CYCLE OF REFINEMENT AND FURTHER EXPERIMENTATION IN SEARCH OF MEDICAL ADVANCES, WHETHER A NEW DIAGNOSTIC TEST OR TREATMENT. IN THIS REGARD, TGEN HAS HELPED BRIDGE THE GAP BETWEEN LABORATORY DISCOVERIES AND PRACTICAL APPLICATIONS IN PATIENT CARE. OUR APPROACH HAS LED TO SIGNIFICANT STRIDES IN UNDERSTANDING DISEASES AT THE MOLECULAR LEVEL, PAVING THE WAY FOR MORE PRECISE DIAGNOSTIC TOOLS AND GROUNDBREAKING TREATMENTS. TODAY, OUR CAPACITY TO UNDERSTAND AND LEVERAGE INFORMATION FROM THE HUMAN GENOME HAS NEVER BEEN GREATER. TGEN'S ABILITY TO BRING EMERGING NEW METHODS FOR INTERROGATING A PATIENT'S GENOME INTO THE CLINICAL CARE OF PATIENTS, THE REVOLUTION IN FASTER AND LOWER-COST WAYS OF CANCER DETECTION AND THE PATHS THAT REACH THE URBAN, THE RURAL AND MORE DIVERSE POPULATIONS, HAS NEVER BEEN GREATER. THE SEQUENCE COST PER-PATIENT OVER THE PAST DECADE HAS DROPPED DRAMATICALLY. THIS MEANS TGEN CAN SEQUENCE MORE PATIENTS, OR SEQUENCE A PATIENT AGAIN, TO UNDERSTAND HOW THEIR DISEASE IS PROGRESSING. AS PART OF A NATIONAL HEALTH SYSTEM, THIS HELPS DRIVE RESEARCH DISCOVERY, NEW METHODS FOR EARLY DETECTION, AND MORE CLINICAL TRIALS. SEQUENCING ACCURACY HAS ALSO IMPROVED DRAMATICALLY. THIS INCREASED ACCURACY MEANS TGEN CAN DETECT CANCER EARLIER - PERHAPS IN ITS INFANCY - WHICH LEADS TO IMPROVED SCREENING, POST-TREATMENT MONITORING AND BIOPSIES WITH A LOW PERCENTAGE OF TUMOR PRESENT. THIS ALSO ALLOWS US TO EXPAND GENOMIC TESTING INTO MORE CANCER TYPES. BECKMAN RESEARCH INSTITUTE 1450 EAST DUARTE ROAD DUARTE CA 91010 953432210 RESEARCH CA 501(c)(3) 4 CITY OF HOPE true CITY OF HOPE 1500 EAST DUARTE ROAD DUARTE CA 91010 953435919 FUNDRAISING CA 501(c)(3) 7 NA false CITY OF HOPE MEDICAL FOUNDATION 1500 EAST DUARTE ROAD DUARTE CA 91010 272803222 HEALTHCARE CA 501(c)(3) 3 CITY OF HOPE true CITY OF HOPE NATIONAL MEDICAL CENTER 1500 EAST DUARTE ROAD DUARTE CA 91010 951683875 HOSPITAL CA 501(c)(3) 3 CITY OF HOPE true COH HOLDCO INC 1500 EAST DUARTE ROAD DUARTE CA 91010 873651176 SUPPORT DE 501(c)(3) Type III-FI CITY OF HOPE true Midwestern Regional Medical Center Inc 1500 East Duarte Road Duarte CA 91010 362510771 Hospital IL 501(c)(3) 3 COH HOLDCO INC true Southeastern Regional Medical Center Inc 1500 East Duarte Road Duarte CA 91010 264572436 Hospital GA 501(c)(3) 3 COH HOLDCO INC true THE TRANSLATIONAL GENOMIC RESEARCH INSTITUTE 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 753065445 RESEARCH AZ 501(c)(3) 7 CITY OF HOPE true Western Regional Medical Center Inc 1500 East Duarte Road Duarte CA 91010 320197974 Hospital AZ 501(c)(3) 3 COH HOLDCO INC true SOUTHERN CA RADIATION ONCOLOGY 1500 EAST DUARTE ROAD DUARTE CA 91010 364887584 MGMT SERVICES CA NA N/A 0 0 false false ACCESSHOPE LLC 1500 EAST DUARTE ROAD DUARTE CA 91010 842818450 ONCOLOGY SUPPORT CA NA N/A 0 0 false false false true false false false false false false false false false true false true true false false false false THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE B 9708783 ACTUAL COST